Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization
Shin-ichiro Kiyose
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
In Vitro Diagnostics (IVD) R&D Department, Jokoh Co., Ltd., Tokyo
Search for more papers by this authorKiyoko Nagura
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
In Vitro Diagnostics (IVD) R&D Department, Jokoh Co., Ltd., Tokyo
Search for more papers by this authorHong Tao
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Search for more papers by this authorHisaki Igarashi
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Search for more papers by this authorHidetaka Yamada
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Search for more papers by this authorMasanori Goto
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Search for more papers by this authorMatsuyoshi Maeda
Department of Pathology, Toyohashi Municipal Hospital, Toyohashi, Japan
Search for more papers by this authorNobuya Kurabe
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Search for more papers by this authorMasaya Suzuki
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Search for more papers by this authorMasaru Tsuboi
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Search for more papers by this authorTomoaki Kahyo
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Search for more papers by this authorKazuya Shinmura
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Search for more papers by this authorNaohiko Hattori
In Vitro Diagnostics (IVD) R&D Department, Jokoh Co., Ltd., Tokyo
Search for more papers by this authorCorresponding Author
Haruhiko Sugimura
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Haruhiko Sugimura, MD, Department of Tumor Pathology, Hamamatsu University School of Medicine, 1-20-1, Handayama, Higashi-ku, Hamamatsu, 431-3192 Japan. Email: [email protected]Search for more papers by this authorShin-ichiro Kiyose
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
In Vitro Diagnostics (IVD) R&D Department, Jokoh Co., Ltd., Tokyo
Search for more papers by this authorKiyoko Nagura
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
In Vitro Diagnostics (IVD) R&D Department, Jokoh Co., Ltd., Tokyo
Search for more papers by this authorHong Tao
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Search for more papers by this authorHisaki Igarashi
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Search for more papers by this authorHidetaka Yamada
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Search for more papers by this authorMasanori Goto
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Search for more papers by this authorMatsuyoshi Maeda
Department of Pathology, Toyohashi Municipal Hospital, Toyohashi, Japan
Search for more papers by this authorNobuya Kurabe
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Search for more papers by this authorMasaya Suzuki
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Search for more papers by this authorMasaru Tsuboi
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Search for more papers by this authorTomoaki Kahyo
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Search for more papers by this authorKazuya Shinmura
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Search for more papers by this authorNaohiko Hattori
In Vitro Diagnostics (IVD) R&D Department, Jokoh Co., Ltd., Tokyo
Search for more papers by this authorCorresponding Author
Haruhiko Sugimura
Department of Tumor Pathology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu
Haruhiko Sugimura, MD, Department of Tumor Pathology, Hamamatsu University School of Medicine, 1-20-1, Handayama, Higashi-ku, Hamamatsu, 431-3192 Japan. Email: [email protected]Search for more papers by this authorConflict of Interest: Shinichiro Kiyose and Naohiko Hattori are employees of JOKOH Co. Ltd.
Abstract
To test the feasibility of using bacterial artificial chromosomes (BAC) containing kinases for pathological diagnosis using fluorescence in situ hybridization (FISH), 10 BAC probes containing a gene amplified in 5% or more of a pilot cohort were selected from a previous survey using arbitrarily selected BAC clones harboring 100 kinases. In this report, we describe the prevalence and association with the clinico-pathological profile of these selected 10 BAC probes in 365 gastric cancer tissues. FISH analyses using these 10 BAC probes containing loci encoding EGFR, ERBB2(HER2), EPHB3, PIK3CA, MET, PTK7, ACK1, STK15, SRC, and HCK showed detectable amplifications in paraffin-embedded tissue in 2.83% to 13.6% of the gastric cancer tissues. Considerable numbers of the cases showed the co-amplification of two or more of the probes that were tested. BAC probes located within a genome neighborhood, such as PIK3CA, EPHB3, and ACK1 at 3q26-29 or HCK, SRC, and STK15 at 20q11-13.1, were often co-amplified in the same cases, but non-random co-amplifications of genes at distant genomic loci were also observed. These findings provide basic information regarding the creation of a strategy for personalizing gastric cancer therapy, especially when using multiple kinase inhibitors.
REFERENCES
- 1 Lopez-Otin C, Hunter T. The regulatory crosstalk between kinases and proteases in cancer. Nat Rev Cancer 2010; 10: 278–92.
- 2 Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912–34.
- 3 Kubo T, Kuroda Y, Shimizu H et al. Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer. Carcinogenesis 2009; 30: 1857–64.
- 4 Sugimura H, Mori H, Nagura K et al. Fluorescence in situ hybridization analysis with a tissue microarray: ‘FISH and chips’ analysis of pathology archives. Pathol Int 2010; 60: 543–50.
- 5 Sugimura H. Detection of chromosome changes in pathology archives: An application of microwave-assisted fluorescence in situ hybridization to human carcinogenesis studies. Carcinogenesis 2008; 29: 681–7.
- 6 Mori H, Nagata M, Nishijima N et al. Malignant pheochromocytoma in a young adult forming the structure simulating Homer Wright rosette: Differentiation from neuroblastoma on repeating fluorescence in situ hybridization. Pathol Int 2008; 58: 518–23.
- 7 Suzuki M, Nagura K, Igarashi H et al. Copy number estimation algorithms and fluorescence in situ hybridization to describe copy number alterations in human tumors. Pathol Int 2009; 59: 218–28.
- 8 Shinmura K, Goto M, Suzuki M et al. Reduced expression of MUTYH with suppressive activity against mutations caused by 8-hydroxyguanine is a novel predictor of a poor prognosis in human gastric cancer. J Pathol 2011; 225: 414–23.
- 9 Varella-Garcia M. Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: The EGFR fluorescence in situ hybridization assay. Diagn Pathol 2006; 1: 19.
- 10 Ooi A, Inokuchi M, Harada S et al. Gene amplification of ESR1 in breast cancers-fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. J Pathol 2011; 227: 8–16.
- 11 Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma—2nd English Edition. Gastric Cancer 1998; 1: 10–24.
- 12 Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687–97.
- 13 Watanabe Y, Ikemura T, Sugimura H. Amplicons on human chromosome 11q are located in the early/late-switch regions of replication timing. Genomics 2004; 84: 796–805.
- 14 Perucho M. Cancer of the microsatellite mutator phenotype. Biol Chem 1996; 377: 675–84.
- 15 Crasta K, Ganem NJ, Dagher R et al. DNA breaks and chromosome pulverization from errors in mitosis. Nature 2012; 482: 53–8.
- 16 Kloosterman WP, Guryev V, van Roosmalen M et al. Chromothripsis as a mechanism driving complex de novo structural rearrangements in the germline. Hum Mol Genet 2011; 20: 1916–24.
- 17 Maher CA, Wilson RK. Chromothripsis and human disease: Piecing together the shattering process. Cell 2012; 148: 29–32.
- 18 Rausch T, Jones DT, Zapatka M et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012; 148: 59–71.
- 19 Jaehne J, Urmacher C, Thaler HT, Friedlander-Klar H, Cordon-Cardo C, Meyer HJ. Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J Cancer Res Clin Oncol 1992; 118: 474–9.
- 20 Matsubara J, Yamada Y, Hirashima Y et al. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res 2008; 14: 3022–9.
- 21 Lin W, Kao HW, Robinson D, Kung HJ, Wu CW, Chen HC. Tyrosine kinases and gastric cancer. Oncogene 2000; 19: 5680–89.
- 22 Psyrri A, Papageorgiou S, Liakata E et al. Phosphatidylinositol 3′-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res 2009; 15: 5724–32.
- 23 Okudela K, Suzuki M, Kageyama S et al. PIK3CA mutation and amplification in human lung cancer. Pathol Int 2007; 57: 664–71.
- 24 Ji M, Guan H, Gao C, Shi B, Hou P. Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer 2011; 11: 147.
- 25 Jehan Z, Bavi P, Sultana M et al. Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer. J Pathol 2009; 219: 337–46.
- 26 Kong D, Yamori T. Phosphatidylinositol 3-kinase inhibitors: Promising drug candidates for cancer therapy. Cancer Sci 2008; 99: 1734–40.
- 27
Sugimura H,
Wang JD,
Mori H
et al.
EPH-EPHRIN in human gastrointestinal cancers.
World J Gastrointest Oncol
2011; 2: 421–8.
10.4251/wjgo.v2.i12.421 Google Scholar
- 28 Ji XD, Li G, Feng YX et al. EphB3 is overexpressed in non-small-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration. Cancer Res 2011; 71: 1156–66.
- 29 Kang JU, Koo SH, Kwon KC, Park JW, Kim JM. Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung. BMC Cancer 2009; 9: 237.
- 30 van der Horst EH, Degenhardt YY, Strelow A et al. Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proc Natl Acad Sci U S A 2005; 102: 15901–6.
- 31 Gorringe KL, Boussioutas A, Bowtell DD. Novel regions of chromosomal amplification at 6p21, 5p13, and 12q14 in gastric cancer identified by array comparative genomic hybridization. Genes Chromosomes Cancer 2005; 42: 247–59.
- 32 Lu XY, Lu Y, Zhao YJ et al. Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res 2008; 6: 937–46.
- 33 Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas: Prognostic significance of protein overexpression and high gene copy number. Histopathology 2008; 52: 738–46.
- 34 Ooi A, Zen Y, Ninomiya I et al. Gene amplification of ERBB2 and EGFR in adenocarcinoma in situ and intramucosal adenocarcinoma of Barrett's esophagus. Pathol Int 2010; 60: 466–71.
- 35 Liang Z, Zhang J, Zeng X, Gao J, Wu S, Liu T. Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer 2010; 10: 376.
- 36 Suzuki M, Kageyama S, Shinmura K et al. Inverse relationship between the length of the EGFR CA repeat polymorphism in lung carcinoma and protein expression of EGFR in the carcinoma. J Surg Oncol 2008; 98: 457–61.
- 37 Tsujimoto H, Sugihara H, Hagiwara A, Hattori T. Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. Virchows Arch 1997; 431: 383–9.
- 38 Kim ES, Salgia R. MET pathway as a therapeutic target. J Thorac Oncol 2009; 4: 444–7.
- 39 Go H, Jeon YK, Park HJ, Sung SW, Seo JW, Chung DH. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol 2010; 5: 305–13.
- 40 Sattler M, Salgia R. The MET axis as a therapeutic target. Update. Cancer Ther 2009; 3: 109–18.
- 41 Okamoto W, Okamoto I, Yoshida T et al. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition. Mol Cancer Ther 2010; 9: 1188–97.
- 42 Yano T, Doi T, Ohtsu A et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006; 15: 65–71.
- 43 Risio M, De Rosa G, Sarotto I et al. HER2 testing in gastric cancer: Molecular morphology and storage time-related changes in archival samples. Int J Oncol 2003; 23: 1381–7.
- 44 Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol 2011; 18: 53–9.
- 45 Lee F, Fandi A, Voi M. Overcoming kinase resistance in chronic myeloid leukemia. Int J Biochem Cell Biol 2008; 40: 334–43.
- 46 Haura EB, Tanvetyanon T, Chiappori A et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 1387–94.
- 47 Levitt JM, Yamashita H, Jian W, Lerner SP, Sonpavde G. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. Mol Cancer Ther 2010; 9: 1128–35.
- 48 Matsuo K, Nishimura M, Bottsford-Miller JN et al. Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res 2011; 17: 5367–78.
- 49 Klein A, Reichardt W, Jung V, Zang KD, Meese E, Urbschat S. Overexpression and amplification of STK15 in human gliomas. Int J Oncol 2004; 25: 1789–94.
- 50 Yang SB, Zhou XB, Zhu HX et al. Amplification and overexpression of Aurora-A in esophageal squamous cell carcinoma. Oncol Rep 2007; 17: 1083–8.
- 51 Li Y, Li F, Li-Ling J, Wang X, Xu Z, Sun K. STK15 gene overexpression, centrosomal amplification, and chromosomal instability in the absence of STK15 mutations in laryngeal carcinoma. Cancer Invest 2005; 23: 660–64.
- 52 Lentini L, Amato A, Schillaci T, Di Leonardo A. Simultaneous Aurora-A/STK15 overexpression and centrosome amplification induce chromosomal instability in tumour cells with a MIN phenotype. BMC Cancer 2007; 7: 212.
- 53 Akahane D, Tauchi T, Okabe S, Nunoda K, Ohyashiki K. Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: In vitro and in vivo studies. Cancer Sci 2008; 99: 1251–7.
- 54 Gontarewicz A, Danusertib BTH. Formerly PHA-739358)—a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. Recent Results Cancer Res 2010; 184: 199–214.
- 55 Wang Y, Shinmura K, Guo RJ et al. Mutational analyses of multiple target genes in histologically heterogeneous gastric cancer with microsatellite instability. Jpn J Cancer Res 1998; 89: 1284–91.
Citing Literature
